NIFTY200 Alpha 30

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Adani Energy Solutions has informed that the Company will interact with the investors / analysts as per schedule enclosed. Further, the presentation for the above meeting is available on the Company’s Website at www.adanienergysolutions.com.

The above information is a part of company’s filings submitted to BSE.  

Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) SingleDose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418]. 

The above information is a part of company’s filings submitted to BSE.  

Aditya Birla Capital has informed that the NBFC business of the company (‘ABCL’), one of India's leading diversified financial services companies, today announced its entry into the Gold Loan business, marking a strategic expansion of its secured lending portfolio. The Gold Loan offering complements its existing retail and MSME lending franchise, providing customers with a transparent, flexible and collateral-backed credit solution. The Company has planned a phase-wise rollout of 200-300 dedicated Gold Loan branches by March 2027 across high-potential markets. Over the next three years, the ABCL-NBFC business aims to establish a network of around 1,000 Gold Loan branches, building a strong pan-India franchise and further strengthening its presence across the country. A Press Release on the same is enclosed.

The above information is a part of company’s filings submitted to BSE. 

Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Glenmark) today announced the receipt of U.S. FDA approval1 for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. Glenmark’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase®2 Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121] and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.